### ü´† Cardiology: Refractory Angina Management

#### ‚úÖ True Statements
1. **External counterpulsation (ECP)** and **spinal cord stimulation** have demonstrated **antianginal benefit** in patients with **refractory angina** who have **exhausted standard revascularization options** and remain symptomatic despite **optimal medical therapy**.
2. **External counterpulsation (ECP)** uses **three sets of pneumatic cuffs** that contract sequentially on the **lower extremities** to **augment venous return**, **increase aortic diastolic pressure**, and **enhance coronary artery blood flow**.
3. **External counterpulsation (ECP)** is generally well tolerated and effective in **reducing angina symptoms** and **increasing exercise tolerance**, even though patients with **marked left ventricular systolic dysfunction** may tolerate it less well.
4. **Repeat anatomic testing** (e.g., **coronary angiography**, **cardiac magnetic resonance viability assessment**) or **functional testing** (e.g., **regadenoson myocardial perfusion imaging**) is **not indicated** in patients with **stable symptoms** and previously documented **unrevascularizable coronary disease**.
5. **Dual antiplatelet therapy (DAPT)** with **clopidogrel** and **aspirin** is **not indicated** as an antianginal strategy and may **increase bleeding risk** without benefit in patients **without recent stenting** or **acute coronary syndrome**.

#### üí¨ Extra
1. This patient has persistent **lifestyle-limiting anginal symptoms** despite **maximally tolerated medical therapy** and **no standard revascularization options**, making **ECP** the most appropriate management.
2. The mechanism of action mimics **diastolic augmentation**, improving myocardial perfusion.
3. Intermittent use allows most patients to **tolerate volume shifts**, especially when **left ventricular function is preserved**.
4. Repeat imaging may be warranted only in cases of **changing symptoms**, particularly **acute coronary syndrome**, which could reveal newly **treatable disease**.
5. **Clopidogrel** is indicated for **secondary prevention** after **stent placement** or **acute coronary syndrome**, not for chronic stable angina alone.

#### üî∑ Tags
#Cardiology #AmbulatoryCare #PatientOver65

#### üìô Reference
Povsic TJ, Henry TD, Ohman EM. Therapeutic approaches for the no-option refractory angina patient. *Circ Cardiovasc Interv*. 2021;14:e009002. PMID: 33541098 doi:10.1161/CIRCINTERVENTIONS.120.009002

#### üÜî Question ID
CVMCQ24011

#### üïí Last Updated
January 2025

---

#### üìñ Related Text
MKSAP 19: Cardiovascular Medicine ‚Äî Coronary Artery Disease, Stable Angina Pectoris, General Approach to Treatment of Stable Ischemic Heart Disease

---

### üìò Related Text Derivations

#### ‚úÖ True Statements
1. **Œ≤-Blockers**, **calcium channel blockers**, and **nitrates** are effective first-line antianginal medications in patients with **stable chronic angina**.
2. **Œ≤-Blockers** relieve angina by reducing **heart rate**, **myocardial contractility**, and **blood pressure**, thereby lowering **myocardial oxygen demand**.
3. All **Œ≤-blockers** are equally effective in managing angina symptoms, with choice influenced by comorbidities.
4. In patients with **chronic lung disease**, **Œ≤‚ÇÅ-selective Œ≤-blockers** such as **metoprolol** and **bisoprolol** are preferred to minimize pulmonary side effects.
5. In patients with **reduced left ventricular function**, **metoprolol succinate**, **bisoprolol**, and **carvedilol** reduce **long-term mortality**.
6. **Nondihydropyridine calcium channel blockers**, such as **diltiazem** and **verapamil**, are contraindicated in **left ventricular systolic dysfunction** due to negative inotropic effects.
7. **Short-acting dihydropyridines**, like **nifedipine**, should be avoided in angina due to reflex tachycardia and increased myocardial oxygen demand.
8. **Nitrates** lower myocardial oxygen demand by **reducing preload**, which decreases **ventricular wall stress**.
9. **Long-acting nitrate therapy** must include a **daily nitrate-free interval of 8 to 12 hours** to prevent **tolerance**.
10. **Ranolazine** does not significantly lower blood pressure or heart rate and has **no proarrhythmic effects**, despite its **QT-prolonging property**.
11. **Strong CYP3A4 inhibitors**, including **clarithromycin**, **itraconazole**, and **ketoconazole**, are contraindicated with **ranolazine** due to increased risk of toxicity.
12. **Ivabradine**, an If current inhibitor, is not recommended in the U.S. for treating **stable coronary disease without heart failure**.
13. **All patients with angina or a history of ischemic events** should receive **guideline-directed medical therapy**, including **risk factor modification**, **cardioprotective medications**, and **antianginal medications** to improve functional capacity.
14. In **stable angina**, **low-dose aspirin** is indicated in all patients without contraindication; **clopidogrel** is an acceptable alternative in aspirin-intolerant patients.
15. **High-intensity statin therapy** is a cornerstone of treatment in **coronary artery disease (CAD)** due to its benefit in reducing **myocardial infarction (MI)**, **stroke**, and **death**.
16. In **type 2 diabetes mellitus** and **stable CAD**, a **SGLT2 inhibitor** or **GLP-1 receptor agonist** is the preferred treatment for diabetes.
17. **ACE inhibitors** are indicated in **stable angina** with **diabetes**, **chronic kidney disease**, **left ventricular dysfunction**, or **heart failure**.
18. **Ranolazine** reduces **angina** without affecting **blood pressure**, and is useful in patients with **persistent symptoms** despite optimized therapy.
19. **External enhanced counterpulsation** may be considered for **refractory angina** in patients not eligible for **revascularization**.
20. **Ezetimibe** and **PCSK9 inhibitors** may be used in patients not at LDL goal on statin therapy.
21. **Icosapent ethyl** provides additional risk reduction in patients with **hypertriglyceridemia** when added to statins.
22. **Œ≤‚ÇÅ-selective Œ≤-blockers** such as **metoprolol** and **bisoprolol** are preferred in patients with **lung disease**.
23. **Long-acting nitrates** require a **nitrate-free interval** of 8‚Äì12 hours to prevent **tolerance**.
24. **Ranolazine** reduces **wall tension** and **myocardial oxygen consumption** through **late sodium current inhibition**.
25. **Ranolazine** requires **dose reduction** with **moderate CYP3A4 inhibitors** and **avoidance** with **strong CYP3A4 inhibitors**.
26. **Coronary sinus reducer implantation** is an emerging **device therapy** for **refractory angina**.

#### üí¨ Extra
1. These medications balance myocardial oxygen supply and demand.
2. Oxygen demand reduction is key in exertional angina.
3. Œ≤-blocker choice may depend on comorbid hypertension, kidney disease, or lung disease.
4. Nonselective agents (e.g., propranolol) can worsen asthma or COPD.
5. These agents have been proven in large-scale trials for HFrEF.
6. Negative inotropes reduce contractility and can worsen heart failure.
7. Reflex tachycardia increases cardiac work and ischemia.
8. Nitrates relieve symptoms by reducing cardiac filling pressures.
9. Tolerance reduces therapeutic effectiveness unless nitrate-free intervals are observed.
10. This makes ranolazine ideal for patients who cannot tolerate hemodynamic changes.
11. These inhibitors increase ranolazine serum levels by preventing metabolism.
12. Ivabradine use is restricted by U.S. guidelines to HFrEF and not angina.
16. These agents provide both glycemic control and cardiovascular benefit, especially in patients with coexisting CAD.
18. Choice among these agents depends on comorbidities such as heart failure, arrhythmia, or hypotension.
21. Inclisiran and bempedoic acid may be considered in select statin-intolerant or high-risk patients.
24. Common moderate **CYP3A4 inhibitors** include **verapamil** and **diltiazem**.
25. QT monitoring is advised due to ranolazine's electrophysiologic effects, especially in elderly or polypharmacy patients.
26. The **coronary sinus reducer** increases pressure in the coronary venous system to improve subendocardial perfusion.

#### üî∑ Tags
#Cardiology #StableAngina #AntianginalTherapy #BetaBlocker #CalciumChannelBlocker #NitrateTolerance #Ranolazine #QTProlongation #Ivabradine #Statins #Aspirin #Clopidogrel #CAD #CKD #GLP1 #SGLT2 #DeviceTherapy #CoronarySinusReducer #RefractoryAngina

---

#### üßæ Supplemental Tables

<table>
  <caption><strong>Medical Therapy for Acute Coronary Syndromes and Angina</strong></caption>
  <thead>
    <tr>
      <th>Medication</th>
      <th>Drugs in Class</th>
      <th>Dosage</th>
      <th>Indications</th>
      <th>Comments</th>
    </tr>
  </thead>
  <tbody>
    <!-- Antiplatelet Medications -->
    <tr><td colspan="5"><strong>Antiplatelet Medications</strong></td></tr>
    <tr>
      <td><strong>Aspirin</strong></td>
      <td>N/A</td>
      <td>81‚Äì162 mg/d</td>
      <td>All patients with acute coronary syndrome (ACS), unless intolerant or allergic.<br>All patients with angina.<br>Aspirin desensitization may be considered for patients with allergy.</td>
      <td>Nonenteric formulation recommended for aspirin-naive patients with ACS.</td>
    </tr>
    <tr>
      <td><strong>Clopidogrel</strong></td>
      <td>N/A</td>
      <td>75 mg/d</td>
      <td>P2Y<sub>12</sub> inhibitor in combination with aspirin is indicated in all patients after ACS for at least 1 year.</td>
      <td>Alternative to aspirin for patients with stable coronary artery disease (CAD) and aspirin intolerance or allergy.</td>
    </tr>
    <tr>
      <td><strong>Prasugrel</strong></td>
      <td>N/A</td>
      <td>10 mg/d</td>
      <td>P2Y<sub>12</sub> inhibitor with aspirin indicated after ACS if PCI is performed. Not used before coronary angiography.</td>
      <td>Contraindicated if age >75 or history of stroke/TIA. Adjust to 5 mg/d if weight &lt;60 kg (132 lb).</td>
    </tr>
    <tr>
      <td><strong>Ticagrelor</strong></td>
      <td>N/A</td>
      <td>90 mg twice daily</td>
      <td>P2Y<sub>12</sub> inhibitor in combination with aspirin is indicated in all patients after ACS for at least 1 year.</td>
      <td>Faster onset; no first-pass hepatic metabolism; no known genetic polymorphisms. Higher bleeding risk with aspirin &gt;100 mg.</td>
    </tr>
    <!-- Cardioprotective Medications -->
    <tr><td colspan="5"><strong>Cardioprotective Medications</strong></td></tr>
    <tr>
      <td><strong>Œ≤-Blockers</strong></td>
      <td>Atenolol, metoprolol, carvedilol, nebivolol, bisoprolol</td>
      <td>Variable</td>
      <td>All patients with prior myocardial infarction (MI) or LV systolic dysfunction (only metoprolol succinate, carvedilol, or bisoprolol).<br>Angina.</td>
      <td>Avoid in cardiogenic shock, hypotension, or conduction disturbances.</td>
    </tr>
    <tr>
      <td><strong>ACE Inhibitors</strong></td>
      <td>Benazepril, captopril, enalapril, fosinopril, perindopril, trandolapril, lisinopril, ramipril, quinapril</td>
      <td>Variable</td>
      <td>All patients with LV systolic dysfunction, hypertension, diabetes mellitus, or kidney disease.</td>
      <td>Especially beneficial in anterior MI.</td>
    </tr>
    <tr>
      <td><strong>Angiotensin Receptor Blockers</strong></td>
      <td>Losartan, valsartan, olmesartan, candesartan, irbesartan, telmisartan</td>
      <td>Variable</td>
      <td>All patients with LV systolic dysfunction, hypertension, diabetes, or kidney disease who are intolerant of ACE inhibitors.</td>
      <td>Should not be combined with ACE inhibitors.</td>
    </tr>
    <tr>
      <td><strong>Aldosterone Inhibitor</strong></td>
      <td>Eplerenone</td>
      <td>25‚Äì50 mg/d</td>
      <td>Patients with STEMI with LVEF ‚â§40% and either clinical heart failure or diabetes.</td>
      <td>Use caution in chronic kidney disease or hyperkalemia.</td>
    </tr>
    <tr>
      <td><strong>High-Intensity Statins</strong></td>
      <td>Atorvastatin, Rosuvastatin</td>
      <td>Atorvastatin 40‚Äì80 mg/d<br>Rosuvastatin 20‚Äì40 mg/d</td>
      <td>All patients with CAD and age ‚â§75 years.</td>
      <td>‚Äî</td>
    </tr>
    <tr>
      <td><strong>Moderate-Intensity Statins</strong></td>
      <td>Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Lovastatin, Fluvastatin</td>
      <td>10‚Äì40 mg/d depending on agent</td>
      <td>All patients with CAD and age &gt;75 years or who are statin intolerant.</td>
      <td>Simvastatin limited to 20 mg/d if using amlodipine.</td>
    </tr>
    <!-- Antianginal Medications -->
    <tr><td colspan="5"><strong>Antianginal Medications</strong></td></tr>
    <tr>
      <td><strong>Nitroglycerin</strong></td>
      <td>Sublingual, Oral, IV</td>
      <td>Sublingual: 0.4 mg q5min √ó3<br>IV: 5‚Äì10 Œºg/min initial infusion</td>
      <td>Chest pain relief; IV for persistent pain, heart failure, or hypertension.</td>
      <td>Avoid with SBP &lt;90 or ‚â•30 mmHg drop, RV infarction, PDE-5 inhibitors, HCM, or AS.</td>
    </tr>
    <tr>
      <td><strong>Dihydropyridine Calcium Channel Blockers</strong></td>
      <td>Amlodipine</td>
      <td>5‚Äì10 mg/d</td>
      <td>BP control and angina in hypertensive patients.</td>
      <td>Careful dose titration due to delayed onset.</td>
    </tr>
    <tr>
      <td><strong>Nondihydropyridine Calcium Channel Blockers</strong></td>
      <td>Diltiazem, Verapamil</td>
      <td>Variable</td>
      <td>For patients with NSTE-ACS and angina intolerant to or refractory to Œ≤-blockers and nitrates.</td>
      <td>Contraindicated in STEMI, heart failure, or AV block.</td>
    </tr>
    <tr>
      <td><strong>Ranolazine</strong></td>
      <td>‚Äî</td>
      <td>500‚Äì1000 mg twice daily</td>
      <td>For angina refractory to other therapies. No meaningful HR or BP effect.</td>
      <td>QT-prolonging; reduce dose with CYP3A4 inhibitors. Avoid in cirrhosis.</td>
    </tr>
  </tbody>
  <tfoot>
    <tr>
      <td colspan="5">
        <em>
          ACS = acute coronary syndrome; AS = aortic stenosis; BP = blood pressure; CAD = coronary artery disease;
          CYP450 3A4 = cytochrome P-450 3A4; HCM = hypertrophic cardiomyopathy; IV = intravenous;
          LV = left ventricular; LVEF = left ventricular ejection fraction; MI = myocardial infarction;
          N/A = not applicable; NSTE-ACS = non‚ÄìST-elevation acute coronary syndrome; PCI = percutaneous coronary intervention;
          PDE-5 = phosphodiesterase 5; RV = right ventricular; SBP = systolic blood pressure;
          SL = sublingual; STEMI = ST-elevation myocardial infarction; TIA = transient ischemic attack.
        </em>
      </td>
    </tr>
  </tfoot>
</table>


<!-- Canadian Cardiovascular Society Angina Classification -->
<table>
  <caption><strong>Canadian Cardiovascular Society Angina Classification</strong></caption>
  <thead>
    <tr>
      <th>Class</th>
      <th>Angina Symptom Triggers</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>I</td>
      <td>Angina primarily with strenuous or rapid activity; no angina at rest or with ordinary activities</td>
    </tr>
    <tr>
      <td>II</td>
      <td>Angina with moderate physical exertion, including walking more than two city blocks or climbing two flights of stairs at a ‚Äúnormal‚Äù rate, or with rapid walking or hill or stair climbing, or after meals</td>
    </tr>
    <tr>
      <td>III</td>
      <td>Angina with normal activities, including climbing one flight of stairs or walking one city block at a normal pace</td>
    </tr>
    <tr>
      <td>IV</td>
      <td>Angina with minimal physical or mental activity and possibly at rest</td>
    </tr>
  </tbody>
</table>

---

#### üñºÔ∏è Supplemental Figures

<figure>
  <img src="GDMT for Patients With Stable Ischemic Heart Disease.svg" alt="Guideline-Directed Medical Therapy for Patients With Stable Ischemic Heart Disease">
  <figcaption>
    <strong>Guideline-Directed Medical Therapy for Patients With Stable Ischemic Heart Disease.</strong><br>
    ACC = American College of Cardiology; ACEI = ACE inhibitor; AHA = American Heart Association; ARB = angiotensin receptor blocker; BB = Œ≤-blocker; BID = twice daily; BP = blood pressure; CPAP = continuous positive airway pressure; eGFR = estimated glomerular filtration rate; GLP-1 = glucagon-like peptide 1; HbA1c = hemoglobin A1c; LDL-C = LDL cholesterol; MI = myocardial infarction; PCSK9 = proprotein convertase subtilisin/kexin type 9; SGLT2 = sodium-glucose cotransporter 2; TG = triglycerides.<br>
    <sup>a</sup>Consider goal blood pressure of less than 140/80 mm Hg in patients older than 75 years.<br>
    <sup>b</sup>If the patient is at very high risk with LDL ‚â•55 mg/dL (1.42 mmol/L).<br>
    Adapted with permission from: Katz D, Gavin MC. Stable ischemic heart disease. <em>Ann Intern Med</em>. 2019;171:ITC26. PMID: 31382288. ¬©2019 American College of Physicians.
  </figcaption>
</figure>

<figure>
  <img src="Management of Stable Angina Pectoris.svg" alt="Management of Stable Angina Pectoris">
  <figcaption>
    <strong>Management of Stable Angina Pectoris.</strong><br>
    PCI = percutaneous coronary intervention.<br>
    Recommendations based on: Virani SS, Newby LK, Arnold SV, et al; Peer Review Committee Members. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. <em>Circulation</em>. 2023;148:e9-e119. PMID: 37471501 doi:10.1161/CIR.0000000000001168
  </figcaption>
</figure>
